"Re-Purposed" Drugs, Meet the Human Eye!

The Challenges of Re-Purposed Drugs for Ocular Indications

Drugs that were originally developed for diseases ranging from cancer to depression are now being developed for ocular indications. These “re-purposed” drugs can be developed with less risk of failure since their systemic toxicology/safety profiles are already known, and their molecular targets may be validated.  Oncology drugs (e.g., Avastin) are used to arrest vision loss due to wet age-related macular generation (AMD).  Nucleoside reverse transcriptase inhibitors (NRTIs) which were the first generation of HIV/AIDS drugs, are showing promise for currently untreatable dry AMD.  CNS drugs for depression are being evaluated as neuro-protectants for treatment of glaucoma …and so on.

Drug developers entering the ocular space for the first time are finding the eye a challenging environment because of the well-developed mechanisms to protect the eye.  These mechanisms make drug delivery to ocular tissues a particular challenge. Drugs applied topically either overflow onto the face, or flow through the nasolacrimal duct into the nasal passages and the gastrointestinal tract.  Bioavailabilities are typically 2-5% for drugs applied topically. 
The Human Eye

The Davio Pharma Consulting Difference​

 Knowledge to address ocular challenges is specialized technical knowledge.  It is based on experience developing pharmaceutical products in general, and ocular formulations in particular, utilizing fundamental physical and drug delivery science.  Formulation science is coupled with pharmacokinetics and pharmacodynamics to expand understanding, and increase confidence in the new pharmaceutical product.  Davio Pharma Consulting brings the experience, the knowledge, continuous learning, and the passion to address these and other challenges specific to ocular pharmaceutical products.
What is our expertise worth to your company?  Consider the costs of the learning curve.  Davio Pharma Consulting prides itself on open sharing of expertise and knowledge, which will shorten your learning curve, build your internal capability, and get your products on the path to approval in less time than if you go it alone.  How much is this worth to your organization? Development costs can easily top $10,000/week. Delay in approval can cost much more. Let us have a conversation about specific services and then you can decide if we can bring value to your ocular drug development effort.